– USA, MA – Climb Bio, Inc. (Nasdaq: CLYM) announced the appointment of Dr. Doug Williams (Ph.D.) as Chair of its Board of Directors, succeeding of the Board, succeeding Andrew Levin, who will remain on the Board.
The company also announced that Liam Ratcliffe will step down from the board.
About Dr. Douglas E. Williams
Dr. Williams has over 30 years of executive leadership experience in the biotechnology sector. Throughout his career, Dr. Williams has held leadership roles in research and development, contributing significantly to the creation of drugs such as Leukine, Enbrel, Adcetris, Tecfidera, Alprolix, Eloctate, and Spinraza. As a CEO, he has successfully guided both private and public companies from development to commercialization and has overseen multiple successful mergers.
Dr. Williams previously served as the President of Research and Development at Sana Biotechnology and was CEO of Codiak BioSciences. He has also served as EVP of Research and Development at Biogen. Before Biogen, he was CEO at ZymoGenetics and led its acquisition by Bristol Myers Squibb. He has also held a variety of leadership positions, including CSO and EVP of Research and Development at Seattle Genetics (acquired by Pfizer in 2023), SVP and Washington Site Leader at Amgen, and EVP and CTO and a member of the Board of Directors at Immunex (acquired by Amgen in 2021). Dr. Williams has served as a board member of more than a dozen public and private biotechnology companies and is currently Chair of the Board of AC Immune SA and a Director of Stablix.
Dr. Williams said: “I am honored to be joining Climb Bio’s Board at this exciting time as they work to advance budoprutug and build a leading immune-mediated disease focused company. I believe budoprutug has potential across a broad range of B-cell mediated diseases and provides a cornerstone for the company to expand. I look forward to working with the talented Climb Bio team and the board to help them advance their mission to develop therapeutics for patients with immune-mediated diseases.”
Dr. Williams holds a Ph.D. from the State University of New York at Buffalo, Roswell Park Division, and completed a postdoctoral fellowship at Indiana University School of Medicine.
About Climb Bio, Inc.
Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
For more information: https://climbbio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.